55,937 Shares in Bruker Corporation $BRKR Bought by Squarepoint Ops LLC

Squarepoint Ops LLC acquired a new stake in shares of Bruker Corporation (NASDAQ:BRKR) in the second quarter, HoldingsChannel.com reports. The firm acquired 55,937 shares of the medical research company’s stock, valued at approximately $3,366,000.

A number of other institutional investors also recently bought and sold shares of BRKR. Los Angeles Capital Management LLC bought a new stake in shares of Bruker during the 4th quarter valued at about $26,000. Global Retirement Partners LLC bought a new position in shares of Bruker in the 2nd quarter worth approximately $38,000. Parallel Advisors LLC lifted its stake in shares of Bruker by 121.0% in the 4th quarter. Parallel Advisors LLC now owns 875 shares of the medical research company’s stock worth $41,000 after purchasing an additional 479 shares during the period. Allworth Financial LP boosted its holdings in shares of Bruker by 40.6% in the third quarter. Allworth Financial LP now owns 890 shares of the medical research company’s stock worth $29,000 after buying an additional 257 shares during the last quarter. Finally, Essential Partners LLC purchased a new position in shares of Bruker in the first quarter worth approximately $36,000. Institutional investors own 79.52% of the company’s stock.

Bruker Trading Down 0.2%

Bruker stock opened at $53.43 on Friday. The firm has a 50 day moving average of $58.25 and a 200 day moving average of $49.25. The firm has a market capitalization of $8.14 billion, a price-to-earnings ratio of -76.33, a P/E/G ratio of 1.63 and a beta of 1.26. Bruker Corporation has a 12-month low of $30.09 and a 12-month high of $65.30. The company has a current ratio of 1.85, a quick ratio of 0.92 and a debt-to-equity ratio of 0.76.

Bruker (NASDAQ:BRKR) last issued its quarterly earnings results on Tuesday, August 4th. The medical research company reported $0.49 earnings per share for the quarter, beating the consensus estimate of $0.38 by $0.11. The business had revenue of $838.50 million for the quarter, compared to the consensus estimate of $853.57 million. Bruker had a negative net margin of 2.35% and a positive return on equity of 12.47%. The company’s revenue for the quarter was up 5.2% on a year-over-year basis. During the same quarter in the previous year, the firm earned $0.32 earnings per share. Bruker has set its FY 2026 guidance at 2.100-2.150 EPS. As a group, research analysts predict that Bruker Corporation will post 2.12 earnings per share for the current year.

Bruker Dividend Announcement

The company also recently disclosed a quarterly dividend, which will be paid on Wednesday, October 7th. Stockholders of record on Monday, September 21st will be given a dividend of $0.05 per share. This represents a $0.20 annualized dividend and a dividend yield of 0.4%. The ex-dividend date is Monday, September 21st. Bruker’s dividend payout ratio (DPR) is presently -28.57%.

Analyst Upgrades and Downgrades

BRKR has been the subject of a number of research reports. Stifel Nicolaus set a $50.00 target price on shares of Bruker in a report on Wednesday, August 5th. JPMorgan Chase & Co. lifted their price target on shares of Bruker from $55.00 to $65.00 and gave the stock an “overweight” rating in a research note on Monday, June 8th. Guggenheim boosted their price objective on shares of Bruker from $50.00 to $70.00 and gave the company a “buy” rating in a research report on Monday, June 29th. Barclays upped their price objective on Bruker from $53.00 to $60.00 and gave the stock an “overweight” rating in a research note on Wednesday, June 24th. Finally, Weiss Ratings reaffirmed a “sell (d+)” rating on shares of Bruker in a report on Monday, August 31st. One analyst has rated the stock with a Strong Buy rating, six have issued a Buy rating, five have given a Hold rating and two have given a Sell rating to the company’s stock. According to MarketBeat, the stock has an average rating of “Hold” and a consensus price target of $57.00.

About Bruker

Bruker Corporation develops and manufactures scientific instruments, analytical systems and software used to study the chemical, physical and biological properties of materials. Its customers include universities, pharmaceutical and biotechnology companies, industrial manufacturers, hospitals, government laboratories and other research organizations.

The company’s product portfolio includes nuclear magnetic resonance and electron paramagnetic resonance systems, mass spectrometers, X-ray analysis instruments, optical and molecular spectroscopy systems, microscopy and nanoanalysis tools, and instruments for microbiology and spatial biology.